Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Trial of a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With Interleukin-12 With Alum or GM-CSF for Patients With Resected Stages IIB/C, III and IV Melanoma

NCT00031733 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT00031733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00031733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Trial of a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With Interleukin-12 With Alum or GM-CSF for Patients With Resected Stages IIB/C, III and IV Melanoma
Lead sponsor
University of Southern California
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2002
Completion date
November 30, 2007
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intraocular melanoma, melanoma (skin)